Cargando…
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
BACKGROUND: To evaluate the effects of tumor necrosis factor inhibitors (TNFi), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on hemoglobin (Hb) and C-reactive protein (CRP) levels in adults enrolled in CorEvitas (formerly Corrona), a large US rheumatoid arthritis (R...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769058/ https://www.ncbi.nlm.nih.gov/pubmed/36544236 http://dx.doi.org/10.1186/s13075-022-02955-y |
_version_ | 1784854304737198080 |
---|---|
author | Padula, Anthony S. Pappas, Dimitrios A. Fiore, Stefano Blachley, Taylor S. Ford, Kerri Emeanuru, Kelechi Kremer, Joel M. |
author_facet | Padula, Anthony S. Pappas, Dimitrios A. Fiore, Stefano Blachley, Taylor S. Ford, Kerri Emeanuru, Kelechi Kremer, Joel M. |
author_sort | Padula, Anthony S. |
collection | PubMed |
description | BACKGROUND: To evaluate the effects of tumor necrosis factor inhibitors (TNFi), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on hemoglobin (Hb) and C-reactive protein (CRP) levels in adults enrolled in CorEvitas (formerly Corrona), a large US rheumatoid arthritis (RA) registry. METHODS: Patients who initiated TNFi, IL-6Ri, or JAKi treatment during or after January 2010, had Hb and CRP measurements at baseline and 6-month follow-up (± 3 months) and had continued therapy at least until that follow-up, through March 2020, were included in the analysis. Changes in Hb and CRP were assessed at month 6. Abnormal Hb was defined as < 12 g/dL (women) or < 13 g/dL (men); abnormal CRP was ≥ 0.8 mg/dL. Differences in Hb and CRP levels were evaluated using multivariable regression. RESULTS: Of 2772 patients (TNFi, 65%; IL-6Ri, 17%; JAKi, 17%) evaluated, 1044 (38%) had abnormal Hb or CRP at initiation; an additional 252 (9%) had both abnormal Hb and CRP. At month 6, the IL-6Ri group had a greater Hb increase than the TNFi (mean difference in effect on Hb: 0.28 g/dL; 95% CI 0.19–0.38) and JAKi (mean difference in effect on Hb: 0.47 g/dL; 95% CI 0.35–0.58) groups, regardless of baseline Hb status (both p < 0.001). The CRP decrease at month 6 was greater with IL-6Ri compared with TNFi and JAKi, regardless of baseline CRP status (both p < 0.05). CONCLUSION: These real-world results align with the mechanism of IL-6R inhibition and may inform treatment decisions for patients with RA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-022-02955-y. |
format | Online Article Text |
id | pubmed-9769058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97690582022-12-22 The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry Padula, Anthony S. Pappas, Dimitrios A. Fiore, Stefano Blachley, Taylor S. Ford, Kerri Emeanuru, Kelechi Kremer, Joel M. Arthritis Res Ther Research BACKGROUND: To evaluate the effects of tumor necrosis factor inhibitors (TNFi), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on hemoglobin (Hb) and C-reactive protein (CRP) levels in adults enrolled in CorEvitas (formerly Corrona), a large US rheumatoid arthritis (RA) registry. METHODS: Patients who initiated TNFi, IL-6Ri, or JAKi treatment during or after January 2010, had Hb and CRP measurements at baseline and 6-month follow-up (± 3 months) and had continued therapy at least until that follow-up, through March 2020, were included in the analysis. Changes in Hb and CRP were assessed at month 6. Abnormal Hb was defined as < 12 g/dL (women) or < 13 g/dL (men); abnormal CRP was ≥ 0.8 mg/dL. Differences in Hb and CRP levels were evaluated using multivariable regression. RESULTS: Of 2772 patients (TNFi, 65%; IL-6Ri, 17%; JAKi, 17%) evaluated, 1044 (38%) had abnormal Hb or CRP at initiation; an additional 252 (9%) had both abnormal Hb and CRP. At month 6, the IL-6Ri group had a greater Hb increase than the TNFi (mean difference in effect on Hb: 0.28 g/dL; 95% CI 0.19–0.38) and JAKi (mean difference in effect on Hb: 0.47 g/dL; 95% CI 0.35–0.58) groups, regardless of baseline Hb status (both p < 0.001). The CRP decrease at month 6 was greater with IL-6Ri compared with TNFi and JAKi, regardless of baseline CRP status (both p < 0.05). CONCLUSION: These real-world results align with the mechanism of IL-6R inhibition and may inform treatment decisions for patients with RA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-022-02955-y. BioMed Central 2022-12-21 2022 /pmc/articles/PMC9769058/ /pubmed/36544236 http://dx.doi.org/10.1186/s13075-022-02955-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Padula, Anthony S. Pappas, Dimitrios A. Fiore, Stefano Blachley, Taylor S. Ford, Kerri Emeanuru, Kelechi Kremer, Joel M. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry |
title | The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry |
title_full | The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry |
title_fullStr | The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry |
title_full_unstemmed | The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry |
title_short | The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry |
title_sort | effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the corevitas ra registry |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769058/ https://www.ncbi.nlm.nih.gov/pubmed/36544236 http://dx.doi.org/10.1186/s13075-022-02955-y |
work_keys_str_mv | AT padulaanthonys theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT pappasdimitriosa theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT fiorestefano theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT blachleytaylors theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT fordkerri theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT emeanurukelechi theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT kremerjoelm theeffectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT padulaanthonys effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT pappasdimitriosa effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT fiorestefano effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT blachleytaylors effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT fordkerri effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT emeanurukelechi effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry AT kremerjoelm effectoftargetedrheumatoidarthritistherapeuticsonsystemicinflammationandanemiaanalysisofdatafromthecorevitasraregistry |